Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review5-HT1 and 5-HT2C receptor partial agonist (Ki values are 40, 52 and 81 nM for 5-HT1A, 5-HT1B and 5-HT2C receptors respectively). Reduces 5-HIAA levels in the striatum and exhibits antiaggressive behavior in vivo.
分子量 | 256.73 |
公式 | C12H16N2O2.HCl |
储存 | Store at RT |
纯度 | ≥98% (HPLC) |
CAS Number | 98206-09-8 |
PubChem ID | 3025067 |
InChI Key | JFSOSUNPIXJCIX-UHFFFAOYSA-N |
Smiles | Cl.C1CN(CCN1)C1=C2OCCOC2=CC=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Gommans et al (1997) Discriminative stimulus properties of eltoprazine. Life Sci. 61 11 PMID: 9200664
Miczek et al (1989) Brain 5-HT and inhibition of aggressive behavior in animals: 5-HIAA and receptor subtypes. Psychopharmacol.Bull. 25 399 PMID: 2483273
Schipper et al (1990) Neurochemical profile of eltoprazine. Drug Metabol.Drug Interact. 8 85 PMID: 1982626
关键词: Eltoprazine hydrochloride, Eltoprazine hydrochloride supplier, 5-HT2C, receptor, partial, agonists, 5-HT1, Serotonin, Receptors, 5-HT1B, 1860, Tocris Bioscience
目前没有该产品的评论。 Be the first to review Eltoprazine hydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.